Danel (Adir Yeoshua) Ltd (DANE) Fair Value & Analysis
Healthcare · Il · Market cap 2.8B ILA
Fair value as of: Jun 24, 2026
Analysis
Danel (Adir Yeoshua) Ltd (DANE) currently trades at 461.00 ILA, while our model-based Fair Value estimate is 411.88 ILA — implying the stock looks roughly 10.7% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Danel (Adir Yeoshua) Ltd provides human resources services in Israel. The company provides recruitment, placement, and employment services in the areas of finance, insurance, administration, senior management, high-tech, biotech, cleantech, as well as outsourcing project management services, technological employee employment services, and occupational and computerized diagnostic services; payroll services; and nursing and medical services to disabled seniors, ministry of defense beneficiaries, and others. It also manages and operates dormitories and hostels, schools, rehabilitation and therapeutic day centers; and provides Referrals to special schools for complex populations, such as multisystemic learning disabilities, moderate-low functioning autism, intellectual disabilities, mental/emotional difficulties, and behavioral disorders. In addition, the company provides medical services, including surgical activities in ophthalmology field. Danel (Adir Yeoshua) Ltd was incorporated in…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Danel (Adir Yeoshua) Ltd (DANE) undervalued?
What is the fair value of DANE?
What is the quality score of DANE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.